Pandion Therapeutics has collaborated with Astellas Pharma to advance R&D and commercialize immunomodulators for the treatment of auto-immune diseases of the pancreas and other drugs for Type-1 diabetes.
Under the terms of the agreement, Pandion will
be responsible for the design and discovery of bispecific drugs through Pandion’s
proprietary modular immune effector and tissue tether platform.
The deal could yield nearly USD 45 Million to
Pandion upfront and more than USD 750 Million as milestone development and
commercial payments. Moreover, the company might also receive royalties on sales
of commercial products worldwide. On the other hand, Astellas will be in
authority of conducting preclinical, clinical and commercialization of the drug
candidates.
The companies’ main focus will be on treating Type-1 diabetes which results in deterioration of pancreas. Other autoimmune diseases that the collaboration will be working on are Systemic lupus erythematosus and rheumatoid arthritis.
Pear therapeutics and Ironwood Pharmaceuticals
have collaborated to gauge the Prescription Digital Therapeutics (PDTs) for the
treatment of selected Gastrointestinal (GI) diseases.
GI diseases are one of the Pear’s therapeutic areas and so far, the products for substance use disorder and opioid use disorder in the market. Through this agreement, the company is trying to increase its horizon of the pipeline beyond central nervous disorders.
Moreover, Ironwood’s marketed candidate Linzess (linaclotide), which it markets with Allergan and will soon be acquired by AbbVie for USD63 Billion. The drug is indicated for irritable bowel syndrome and chronic idiopathic constipation.
